-
1.发明公开A METHOD FOR DETERMINING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) RELATED BIOMARKERS, A METHOD TO MONITOR THE DEVELOPMENT AND TREATMENT OF ARDS IN A PATIENT 有权方法用于确定用于急性进行肺衰竭和方法生物标记用于监控患者急性呼吸窘迫综合征的发展和治疗
公开(公告)号：EP2956772A4
公开(公告)日：2016-09-14
申请号：EP14752032
申请日：2014-01-22
发明人： MAKSIMOW MIKAEL , SALMI MARKO , JALKANEN MARKKU , JALKANEN SIRPA
IPC分类号： G01N33/573 , A61K38/21 , C07K14/565 , C07K14/705 , C12N9/16 , G01N30/90 , G01N33/68
CPC分类号： G01N33/573 , A61K38/215 , G01N30/90 , G01N33/6884 , G01N33/6893 , G01N2333/70596 , G01N2333/916 , G01N2800/125 , G01N2800/52 , G01N2800/60
摘要： This invention concerns methods for monitoring the development of and for treatment of ARDS in a patient. The method for monitoring the development of ARDS is based on comparing the level or activity of the biomarkers obtained in a sample drawn at a later point of time to the levels or activities of the same biomarkers in a sample drawn at a previous point of time. A favourable change in the level or activity of a certain biomarker represents a regression of the disease (recovery of the patient), and, conversely, an adverse change in the level or activity of a certain biomarker represents a worsening of the disease. If, for example, the level or activity for one or more of the biomarkers monitored discontinues to show a favourable change or starts to show an unfavourable change, the treatment of the patient is enhanced by administering a therapeutically active agent useful in the treatment of ARDS. The invention concerns further a method for simultaneous determination of a multiple of biomarkers in a sample from a patient, wherein said biomarkers are related to ARDS. The level or the activity of the biomarkers is determined. The invention also concerns a diagnostic kit useful for carrying out the method, particularly a kit comprising a chip, such as a microarray suitable for use in biochip technology.
-
2.发明授权LATERAL FLOW IMMUNOASSAY FOR COMPLEMENT ACTIVATION AND METHODS OF USE FOR POINT-OF-CARE ASSESSMENT OF COMPLEMENT-ASSOCIATED DISORDERS 有权克罗斯河免疫试验补体激活和测试方法的使用对补体相关的疾病在提供护理
公开(公告)号：EP2635702B1
公开(公告)日：2016-02-03
申请号：EP11842681.6
申请日：2011-11-02
申请人： Kypha, Inc.
发明人： OLSON, Paul , MOSS, Donald
IPC分类号： G01N33/558 , G01N33/86
CPC分类号： G01N33/68 , G01N33/558 , G01N33/564 , G01N33/86 , G01N2333/4716 , G01N2800/125 , G01N2800/26 , G01N2800/7095
摘要： A method for treating an individual at risk for a complement-associated disorder is provided, the method including: (a) obtaining a sample of a body fluid from the individual; (b) measuring a complement activation level in the sample via a point-of-care lateral flow immunoassay; (c) correlating the complement activation level in the sample to a risk of a complement-associated disorder by comparing the complement activation level in the sample to a reference level in a control, wherein a deviation in complement activation level in the sample compared to the reference level in the control indicates the individual is at risk for a complement-associated disorder; (d) selecting a treatment for the individual, based on the correlating of step (c); and (e) treating the individual with the treatment selected in accordance with step (d).
-
3.发明公开LATERAL FLOW IMMUNOASSAY FOR COMPLEMENT ACTIVATION AND METHODS OF USE FOR POINT-OF-CARE ASSESSMENT OF COMPLEMENT-ASSOCIATED DISORDERS 有权克罗斯河免疫试验补体激活和测试方法的使用对补体相关的疾病在提供护理
公开(公告)号：EP2635702A4
公开(公告)日：2014-04-02
申请号：EP11842681
申请日：2011-11-02
申请人： KYPHA INC
发明人： OLSON PAUL , MOSS DONALD
IPC分类号： C12Q1/56
CPC分类号： G01N33/68 , G01N33/558 , G01N33/564 , G01N33/86 , G01N2333/4716 , G01N2800/125 , G01N2800/26 , G01N2800/7095
摘要： A method for treating an individual at risk for a complement-associated disorder is provided, the method including: (a) obtaining a sample of a body fluid from the individual; (b) measuring a complement activation level in the sample via a point-of-care lateral flow immunoassay; (c) correlating the complement activation level in the sample to a risk of a complement-associated disorder by comparing the complement activation level in the sample to a reference level in a control, wherein a deviation in complement activation level in the sample compared to the reference level in the control indicates the individual is at risk for a complement-associated disorder; (d) selecting a treatment for the individual, based on the correlating of step (c); and (e) treating the individual with the treatment selected in accordance with step (d).
-
4.发明公开MARKER PEPTIDES FOR DETERMINING THE OCCURRENCE OF AN INFLAMMATORY STATE IN A SUBJECT 审中-公开标记肽用于确定点火状态的发生在受试者中
公开(公告)号：EP2334698A1
公开(公告)日：2011-06-22
申请号：EP09764707.7
申请日：2009-10-08
CPC分类号： G01N33/566 , G01N33/6893 , G01N2333/4704 , G01N2800/125 , G01N2800/26 , G01N2800/52
摘要： An enzyme proteolysis-resistant peptide that binds to antibodies directed against the amino acid region 1 -116 of the endocan's polypeptide sequence, which peptide possesses an apparent molecular weight of 14 kDa.
-
5.发明授权USE OF HYPOXIA INDUCIBLE FACTOR 2ALPHA FOR CURING NEONATAL RESPIRATORY DISTRESS SYNDROME 有权的“缺氧诱导因子2alpha”治疗“新生儿呼吸窘迫综合征” USE
公开(公告)号：EP1407276B1
公开(公告)日：2009-10-21
申请号：EP02727576.7
申请日：2002-04-24
申请人： Vlaams Interuniversitair Instituut voor Biotechnologie vzw. , D. Collen Research Foundation vzw
CPC分类号： A61K38/1709 , A61K38/1866 , G01N33/74 , G01N2333/4703 , G01N2500/04 , G01N2800/125 , G01N2800/321 , G01N2800/38
-
公开(公告)号：EP1757937A3
公开(公告)日：2007-04-11
申请号：EP06075291.2
申请日：2000-02-11
发明人： Tracey, Kevin J. , Wang, Haichao
IPC分类号： G01N33/566 , A61K38/00 , C12P21/06
CPC分类号： C07K16/18 , A61K39/395 , A61K39/39533 , A61K2039/505 , C07K16/24 , C07K16/241 , C07K16/2866 , C07K2317/70 , C07K2317/76 , G01N33/6875 , G01N2800/065 , G01N2800/067 , G01N2800/125 , G01N2800/245 , G01N2800/26 , Y02A50/412 , Y02A50/58 , A61K2300/00
摘要： There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of an HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
-
公开(公告)号：EP1165110B1
公开(公告)日：2006-05-31
申请号：EP00915762.9
申请日：2000-02-11
发明人： TRACEY, Kevin, J. , WANG, Haichao
IPC分类号： A61K38/00 , C07K1/00 , C07H21/04 , C12P21/06 , G01N33/566
CPC分类号： C07K16/18 , A61K39/395 , A61K39/39533 , A61K2039/505 , C07K16/24 , C07K16/241 , C07K16/2866 , C07K2317/70 , C07K2317/76 , G01N33/6875 , G01N2800/065 , G01N2800/067 , G01N2800/125 , G01N2800/245 , G01N2800/26 , Y02A50/412 , Y02A50/58 , A61K2300/00
摘要： There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of an HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk or exhibit sepsis or septic shock symptoms. Lastly, there is disclosed a pharmaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment.
-
公开(公告)号：EP2956772B1
公开(公告)日：2018-05-30
申请号：EP14752032.4
申请日：2014-01-22
IPC分类号： G01N33/573 , G01N30/90 , C07K14/705 , C07K14/565 , C12N9/16 , G01N33/68 , A61K38/21
CPC分类号： G01N33/573 , A61K38/215 , G01N30/90 , G01N33/6884 , G01N33/6893 , G01N2333/70596 , G01N2333/916 , G01N2800/125 , G01N2800/52 , G01N2800/60
摘要： This invention concerns methods for monitoring the development of and for treatment of ARDS in a patient. The method for monitoring the development of ARDS is based on comparing the level or activity of the biomarkers obtained in a sample drawn at a later point of time to the levels or activities of the same biomarkers in a sample drawn at a previous point of time. A favourable change in the level or activity of a certain biomarker represents a regression of the disease (recovery of the patient), and, conversely, an adverse change in the level or activity of a certain biomarker represents a worsening of the disease. If, for example, the level or activity for one or more of the biomarkers monitored discontinues to show a favourable change or starts to show an unfavourable change, the treatment of the patient is enhanced by administering a therapeutically active agent useful in the treatment of ARDS. The invention concerns further a method for simultaneous determination of a multiple of biomarkers in a sample from a patient, wherein said biomarkers are related to ARDS. The level or the activity of the biomarkers is determined. The invention also concerns a diagnostic kit useful for carrying out the method, particularly a kit comprising a chip, such as a microarray suitable for use in biochip technology.
-
9.发明公开POINT OF CARE LATERAL FLOW IMMUNOASSAY FOR COMPLEMENT ACTIVATION AND METHODS OF USE FOR POINT-OF-CARE ASSESSMENT OF COMPLEMENT-ASSOCIATED DISORDERS 审中-公开克罗斯河免疫试验FOR USE补有关的疾病测试补体激活和方法在提供护理
公开(公告)号：EP3095876A1
公开(公告)日：2016-11-23
申请号：EP15199549.5
申请日：2011-11-02
申请人： Kypha, Inc.
发明人： OLSON, Paul , MOSS, Donald
IPC分类号： C12Q1/56 , G01N33/564
CPC分类号： G01N33/68 , G01N33/558 , G01N33/564 , G01N33/86 , G01N2333/4716 , G01N2800/125 , G01N2800/26 , G01N2800/7095
摘要： A method for treating an individual at risk for a complement-associated disorder is provided, the method including: (a) obtaining a sample of a body fluid from the individual; (b) measuring a complement activation level in the sample via a point-of-care lateral flow immunoassay; (c) correlating the complement activation level in the sample to a risk of a complement-associated disorder by comparing the complement activation level in the sample to a reference level in a control, wherein a deviation in complement activation level in the sample compared to the reference level in the control indicates the individual is at risk for a complement-associated disorder; (d) selecting a treatment for the individual, based on the correlating of step (c); and (e) treating the individual with the treatment selected in accordance with step (d).
摘要翻译： 提供了一种用于在用于补体相关病症的风险在治疗个体的方法，该方法包括：（a）获得来自所述个体的体液的样品; （b）测量所述样品中经由点的护理横向流动免疫测定补体活化水平; （C）通过比较样品中的控制的参考电平在补体活化水平进行相关样品到补体相关病症的风险中的补体激活电平，worin在样品中的补体激活电平的偏差相比 在控制参考电平指示所述个体处于补体相关病症的风险; （d）选择用于该个体的治疗，基于步骤的相关（C）; 和（e）治疗与雅舞蹈选择与步骤（d）治疗中的个体。
-
10.发明公开A METHOD FOR DETERMINING ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) RELATED BIOMARKERS, A METHOD TO MONITOR THE DEVELOPMENT AND TREATMENT OF ARDS IN A PATIENT 有权方法用于确定用于急性进行肺衰竭和方法生物标记用于监控患者急性呼吸窘迫综合征的发展和治疗
公开(公告)号：EP2956772A1
公开(公告)日：2015-12-23
申请号：EP14752032.4
申请日：2014-01-22
IPC分类号： G01N33/573 , G01N30/90 , C07K14/705 , C07K14/565 , C12N9/16
CPC分类号： G01N33/573 , A61K38/215 , G01N30/90 , G01N33/6884 , G01N33/6893 , G01N2333/70596 , G01N2333/916 , G01N2800/125 , G01N2800/52 , G01N2800/60
摘要： This invention concerns methods for monitoring the development of and for treatment of ARDS in a patient. The method for monitoring the development of ARDS is based on comparing the level or activity of the biomarkers obtained in a sample drawn at a later point of time to the levels or activities of the same biomarkers in a sample drawn at a previous point of time. A favourable change in the level or activity of a certain biomarker represents a regression of the disease (recovery of the patient), and, conversely, an adverse change in the level or activity of a certain biomarker represents a worsening of the disease. If, for example, the level or activity for one or more of the biomarkers monitored discontinues to show a favourable change or starts to show an unfavourable change, the treatment of the patient is enhanced by administering a therapeutically active agent useful in the treatment of ARDS. The invention concerns further a method for simultaneous determination of a multiple of biomarkers in a sample from a patient, wherein said biomarkers are related to ARDS. The level or the activity of the biomarkers is determined. The invention also concerns a diagnostic kit useful for carrying out the method, particularly a kit comprising a chip, such as a microarray suitable for use in biochip technology.
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.016 秒)
